nach oben

Erschienen in:

27.02.2023 | Chronisch-entzündliche Darmerkrankungen | Schwerpunkt

COVID-19 und chronisch-entzündliche Darmerkrankungen

Erschienen in: Die Gastroenterologie | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Pandemie durch die Coronavirus Disease 2019 (COVID-19) beeinflusst weiter das Leben von Patient*innen mit chronisch-entzündlichen Darmerkrankungen (CED). Umfangreiche Untersuchungen der letzten 3 Jahre ergaben, dass die allermeisten Infektionen durch „severe acute respiratory syndrome coronavirus type 2“ (SARS-CoV-2) bei CED-Patient*innen blande verlaufen. In der Regel wird die Krankheitsaktivität der CED nicht negativ beeinflusst; bei einem Teil der Patient*innen können passager gastrointestinale Symptome auftreten. Häufig eingesetzte immunmodulierende Medikamente hatten mit Ausnahme systemischer Glukokortikoide keinen Einfluss auf den Schweregrad einer COVID-19-Erkrankung und die Gesamtletalität unterschied sich nicht von der übrigen Bevölkerung. Die Impfantwort ist jedoch substanzabhängig erniedrigt. In dieser Übersichtsarbeit werden die wichtigsten Studien praxisrelevant zusammengefasst.

Neag MA, Vulturar DM, Gherman D et al (2022) Gastrointestinal microbiota: a predictor of COVID-19 severity? World J Gastroenterol 28:6328–6344CrossRefPubMedPubMedCentral

Grunert PC, Reuken PA, Stallhofer J et al (2020) Inflammatory bowel disease in the COVID-19 pandemic—the patients’ perspective. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjaa126CrossRefPubMed

Reinsch S, Stallmach A, Grunert PC (2021) The COVID-19 pandemic: fears and overprotection in pediatric patients with inflammatory bowel disease and their families. Pediatr Gastroenterol Hepatol Nutr 24:65–74CrossRefPubMedPubMedCentral

Walldorf J, von Arnim U, Schmelz R et al (2021) SARS-CoV‑2 vaccination in patients with inflammatory bowel disease-fear and desire. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izab150CrossRefPubMed

Tinsley A, Navabi S, Williams ED et al (2019) Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis 25:369–376CrossRefPubMed

Ko MK, Ng SC, Mak LY et al (2016) Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis. J Dig Dis 17:610–617CrossRefPubMed

Mao R, Liang J, Shen J et al (2020) Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol 5:425–427CrossRefPubMedPubMedCentral

Norsa L, Indriolo A, Sansotta N et al (2020) Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome Coronavirus 2 outbreak in northern Italy. Gastroenterology 159:371–372CrossRefPubMed

Taxonera C, Sagastagoitia I, Alba C et al (2020) 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 52:276–283CrossRefPubMedPubMedCentral

10.

Allocca M, Chaparro M, Gonzalez HA et al (2020) Patients with inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. J Clin Med 9(11):3533. https://doi.org/10.3390/jcm9113533CrossRefPubMedPubMedCentral

11.

Simon D, Tascilar K, Kronke G et al (2020) Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV‑2 seroconversion. Nat Commun 11:3774CrossRefPubMedPubMedCentral

12.

Eder L, Croxford R, Drucker AM et al (2021) Understanding COVID-19 risk in patients with immune mediated inflammatory diseases: a population-based analysis of SARS-CoV‑2 testing. Arthritis Rheumatism. https://doi.org/10.1002/acr.24781CrossRefPubMed

13.

Schlabitz F, Teich N, Michl P et al (2020) Inflammatory bowel disease and COVID-19-“preventive” sick certificates as a frequent coping strategy in the face of the pandemic. Inflamm Bowel Dis 26:e105–e106CrossRefPubMed

14.

Docherty AB, Harrison EM, Green CA et al (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 369:m1985CrossRefPubMedPubMedCentral

15.

Ungaro RC, Agrawal M, Brenner EJ et al (2021) New gastrointestinal symptoms are common in inflammatory bowel disease patients with COVID-19: data from an international registry. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izab184CrossRefPubMedPubMedCentral

16.

Chebli JMF, Queiroz NSF, Damiao A et al (2021) How to manage inflammatory bowel disease during the COVID-19 pandemic: a guide for the practicing clinician. World J Gastroenterol 27:1022–1042CrossRefPubMedPubMedCentral

17.

Teich N, Ludewig C, Schmelz R et al (2021) Auswirkungen einer SARS-CoV-2-Infektion auf Symptomatik und Therapie chronisch-entzündlicher Darmerkrankungen. Z Gastroenterol 59(11):1189–1196. https://doi.org/10.1055/a-1508-6734CrossRefPubMed

18.

Cheung KS, Hung IFN, Chan PPY et al (2020) Gastrointestinal manifestations of SARS-CoV‑2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 159:81–95CrossRefPubMed

19.

Ghimire S, Sharma S, Patel A et al (2021) Diarrhea is associated with increased severity of disease in COVID-19: systemic review and metaanalysis. SN Compr Clin Med. https://doi.org/10.1007/s42399-020-00662-wCrossRefPubMedPubMedCentral

20.

Gadiparthi C, Perisetti A, Sayana H et al (2020) Gastrointestinal bleeding in patients with severe SARS-CoV‑2. Am J Gastroenterol 115:1283–1285CrossRefPubMed

21.

Ricciuto A, Lamb CA, Benchimol EI et al (2021) Inflammatory bowel disease clinical activity is associated with COVID-19 severity especially in younger patients. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjab172CrossRefPubMedPubMedCentral

22.

Hasseli R, Mueller-Ladner U, Hoyer BF et al (2021) Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7(1):e1464. https://doi.org/10.1136/rmdopen-2020-001464CrossRefPubMed

23.

Strangfeld A, Schafer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 80:930–942CrossRefPubMed

24.

Lukin DJ, Kumar A, Hajifathalian K et al (2020) Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology 159:1541–1544.e2CrossRefPubMed

25.

Brenner EJ, Ungaro RC, Gearry RB et al (2020) Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159:481–491.e3CrossRefPubMed

26.

Ungaro RC, Brenner EJ, Gearry RB et al (2021) Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 70:725–732CrossRefPubMed

27.

Izadi Z, Brenner EJ, Mahil SK et al (2021) Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 4:e2129639CrossRefPubMedPubMedCentral

28.

Melmed GY, Agarwal N, Frenck RW et al (2010) Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 105:148–154CrossRefPubMed

29.

Pratt PK Jr., David N, Weber HC et al (2018) Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on Infliximab therapy. Inflamm Bowel Dis 24:380–386CrossRefPubMed

30.

Caldera F, Hillman L, Saha S et al (2020) Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial. Inflamm Bowel Dis 26:593–602PubMed

31.

Wyant T, Leach T, Sankoh S et al (2015) Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 64:77–83CrossRefPubMed

32.

Kennedy NA, Lin S, Goodhand JR et al (2021) Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV‑2 vaccines in patients with IBD. Gut 70:1884–1893CrossRefPubMed

33.

Reuken PA, Andreas N, Grunert PC et al (2021) T cell response after SARS-CoV‑2 vaccination in immunocompromised patients with inflammatory bowel disease. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjab147CrossRef

34.

Liu Z, Le K, Zhou X et al (2022) Neutralising antibody potency against SARS-CoV‑2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Lancet Gastroenterol Hepatol. https://doi.org/10.1016/S2468-1253(22)00389-2CrossRefPubMedPubMedCentral

35.

Walldorf J, von Arnim U, Schmelz R et al (2021) SARS-CoV‑2 vaccination in patients with inflammatory bowel disease-fear and desire. Inflamm Bowel Dis 27:1858–1861CrossRefPubMed

36.

Selim R, Wellens J, Marlow L et al (2021) SARS-CoV‑2 vaccination uptake by patients with inflammatory bowel disease on biological therapy. Lancet Gastroenterol Hepatol 6:989CrossRefPubMedPubMedCentral

37.

Metz TD, Clifton RG, Hughes BL et al (2021) Disease severity and perinatal outcomes of pregnant patients with Coronavirus disease 2019 (COVID-19). Obstet Gynecol 137:571–580CrossRefPubMedPubMedCentral

38.

Watad A, De Marco G, Mahajna H et al (2021) Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV‑2 vaccination. Vaccines (Basel) 9(5):435. https://doi.org/10.3390/vaccines9050435CrossRefPubMed

39.

Sangha M, Roitman I, Sultan K et al (2021) SARS-CoV‑2 immunization in patients with inflammatory bowel disease may result in disease flares. Am J Gastroenterol. https://doi.org/10.14309/ajg.0000000000001416CrossRefPubMed

40.

Carr EJ, Kronbichler A, Graham-Brown M et al (2021) Review of early immune response to SARS-CoV‑2 vaccination among patients with CKD. Kidney Int Rep 6:2292–2304CrossRefPubMedPubMedCentral

41.

Stallmach A, Carstens O (2002) Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis 8:213–218CrossRefPubMed

42.

Senthamizhselvan K, Ramalingam R, Mohan P et al (2021) De novo Crohn’s disease triggered after COVID-19: is COVID-19 more than an infectious disease? ACG Case Rep J 8:e652CrossRefPubMedPubMedCentral

43.

Elkharsawi A, Arnim UV, Schmelz R et al (2022) SARS-CoV‑2 vaccination does not induce relapses of patients with inflammatory bowel disease. Z Gastroenterol 60:77–80CrossRefPubMed

44.

Piovani D, Danese S, Peyrin-Biroulet L et al (2019) Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157:647–659.e4CrossRefPubMed

45.

Mahmud N, Reinisch W, Patel M et al (2022) Adverse events related to Sars-Cov‑2 vaccine in a nationwide cohort of inflammatory bowel disease patients. Clin Transl Gastroenterol. https://doi.org/10.14309/ctg.0000000000000554CrossRefPubMed

46.

Sattui SE, Liew JW, Kennedy K et al (2021) Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey. RMD Open 7(3):e1814. https://doi.org/10.1136/rmdopen-2021-001814CrossRefPubMed

47.

Geisen UM, Berner DK, Tran F et al (2021) Immunogenicity and safety of anti-SARS-CoV‑2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80:13006–13011CrossRef

48.

Wu Y, Guo C, Tang L et al (2020) Prolonged presence of SARS-CoV‑2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 5:434–435CrossRefPubMedPubMedCentral

49.

Zollner A, Koch R, Jukic A et al (2022) Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 163:495–506.e8CrossRefPubMed

Titel: COVID-19 und chronisch-entzündliche Darmerkrankungen
Publikationsdatum: 27.02.2023
Schlagwörter: Chronisch-entzündliche Darmerkrankungen
Colitis ulcerosa
Morbus Crohn
COVID-19
SARS-CoV-2
SARS-CoV
Impfungen
Erschienen in: Die Gastroenterologie / Ausgabe 2/2023
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-023-00679-2

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

COVID-19 und chronisch-entzündliche Darmerkrankungen

Zusammenfassung

Magen-Darm-Erkrankungen in der Hausarztpraxis

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Mitteilungen des BDI

Versorgung von Lebertransplantierten während der COVID-19-Pandemie

COVID-19 aus Sicht der Gastroenterologie

COVID-19 und Lebererkrankungen

Mitteilungen der NDGG

Mitteilungen der Stiftung LebensBlicke

Magen-Darm-Erkrankungen in der Hausarztpraxis